查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1970508

全球旅行疫苗市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Travel Vaccines Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 142 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

旅行疫苗市場預計將從 2025 年的 58.1 億美元成長到 2034 年的 138.5 億美元，2026 年至 2034 年的複合年成長率為 10.12%。

隨著國際旅行、旅遊業的日益繁榮以及全球勞動力的擴張，旅行疫苗市場正穩步成長。旅行疫苗能夠預防各地流行的感染疾病，對維護公眾健康至關重要。隨著公眾意識的提高和免疫接種宣傳活動的擴大，越來越多的旅客將接種疫苗作為出國旅行前的預防措施。

生物技術創新正在改變市場格局。重組技術、佐劑和無針給藥系統的進步正在提高疫苗的有效性、安全性和患者依從性。能夠抵禦多種病原體的聯合疫苗簡化了免疫接種程序，尤其對經常旅行的人和醫護人員而言更是如此。數位化平台透過預約管理、健康教育和個人化健康建議，進一步提升了疫苗的可近性。

預計未來成長將主要受全球衛生舉措和疫情應對措施的推動。各國政府、非政府組織和私人公司正在增加對疫苗研發、生產和分銷基礎設施的投資。探險旅遊、商務旅行和跨境流動的增加預計將維持強勁的需求。隨著生技和數位醫療的融合，旅遊疫苗市場可望在保障全球流動性和增強抵抗感染疾病的能力方面發揮關鍵作用。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章：全球旅行疫苗市場：依構成

  • 市場分析、洞察與預測
  • 單劑疫苗
  • 聯合疫苗

第5章 全球旅行疫苗市場：依疾病類型分類

  • 市場分析、洞察與預測
  • 甲型肝炎
  • B型肝炎
  • 流感
  • 白喉、百日咳和破傷風（DPT）
  • 狂犬病
  • 黃熱病
  • 傷寒
  • 麻疹和腮腺炎
  • 腦膜炎奈瑟菌
  • 其他疾病疫苗

第6章：全球旅行疫苗市場：依應用領域分類

  • 市場分析、洞察與預測
  • 海外旅行
  • 國內旅行

第7章 全球旅行疫苗市場：按地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • GSK Plc
    • Sanofi
    • Janssen Pharmaceuticals Inc
    • Pfizer Inc
    • CSL Ltd
    • Qiagen NV
    • AstraZeneca
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Valneva Inc
簡介目錄
Product Code: VMR11217083

The Travel Vaccines Market size is expected to reach USD 13.85 Billion in 2034 from USD 5.81 Billion (2025) growing at a CAGR of 10.12% during 2026-2034.

The travel vaccines market is growing steadily as international mobility, tourism, and global workforce expansion increase. Travel vaccines protect against infectious diseases prevalent in different regions, making them essential for safeguarding public health. With rising awareness and expanding vaccination campaigns, more travelers are prioritizing immunization as a preventive measure before international journeys.

Innovation in biotechnology is reshaping the landscape. Advances in recombinant technology, adjuvants, and needle-free delivery systems are improving efficacy, safety, and patient compliance. Combination vaccines that protect against multiple pathogens are simplifying immunization schedules, particularly for frequent travelers and healthcare workers. Digital platforms are further enhancing vaccine accessibility through scheduling, education, and personalized health recommendations.

Future growth will be driven by global health security initiatives and pandemic preparedness. Governments, NGOs, and private companies are investing in vaccine research, production, and distribution infrastructure. The rise of adventure tourism, corporate travel, and cross-border migration is expected to sustain strong demand. As biotechnology and digital health converge, the travel vaccines market is poised to play an integral role in ensuring global mobility and resilience against infectious diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Composition

  • Mono Vaccines
  • Combination Vaccines

By Disease Type

  • Hepatitis A
  • Hepatitis B
  • Influenza
  • Diphtheria Pertussis Tetanus (DPT)
  • Rabies
  • Yellow Fever
  • Typhoid
  • Measles And Mumps
  • Meningococcal
  • Other Disease Vaccines

By Application

  • Outbound Travel
  • Domestic Travel

COMPANIES PROFILED

  • GSK plc, Sanofi, Janssen Pharmaceuticals Inc, Pfizer Inc, CSL Ltd, Qiagen NV, AstraZeneca, F HoffmannLa Roche Ltd, Abbott Laboratories, Valneva Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRAVEL VACCINES MARKET: BY COMPOSITION 2022-2034 (USD MN and Million Doses)

  • 4.1. Market Analysis, Insights and Forecast Composition
  • 4.2. Mono Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 4.3. Combination Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL TRAVEL VACCINES MARKET: BY DISEASE TYPE 2022-2034 (USD MN and Million Doses)

  • 5.1. Market Analysis, Insights and Forecast Disease Type
  • 5.2. Hepatitis A Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.3. Hepatitis B Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.4. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.5. Diphtheria Pertussis Tetanus (DPT) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.6. Rabies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.7. Yellow Fever Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.8. Typhoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.9. Measles And Mumps Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.10. Meningococcal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 5.11. Other Disease Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL TRAVEL VACCINES MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

  • 6.1. Market Analysis, Insights and Forecast Application
  • 6.2. Outbound Travel Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
  • 6.3. Domestic Travel Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL TRAVEL VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.2.1 By Composition
    • 7.2.2 By Disease Type
    • 7.2.3 By Application
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.3.1 By Composition
    • 7.3.2 By Disease Type
    • 7.3.3 By Application
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.4.1 By Composition
    • 7.4.2 By Disease Type
    • 7.4.3 By Application
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.5.1 By Composition
    • 7.5.2 By Disease Type
    • 7.5.3 By Application
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 South East Asia
    • 7.5.9 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
    • 7.6.1 By Composition
    • 7.6.2 By Disease Type
    • 7.6.3 By Application
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TRAVEL VACCINES INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 GSK Plc
    • 9.2.2 Sanofi
    • 9.2.3 Janssen Pharmaceuticals Inc
    • 9.2.4 Pfizer Inc
    • 9.2.5 CSL Ltd
    • 9.2.6 Qiagen N.V
    • 9.2.7 AstraZeneca
    • 9.2.8 F. Hoffmann-La Roche Ltd
    • 9.2.9 Abbott Laboratories
    • 9.2.10 Valneva Inc